Argenx banks on key prefilled syringe approval for Vyvgart to help drive profitability in 2025: exec
As argenx continues to rise to profitability based on the strength of its indication-spanning FcRn inhibitor Vyvgart, a simpler administration route for the med will form a key piece of the Dutch immunology specialist’s expansion plans.
As argenx continues to rise to profitability based on the strength of its indication-spanning FcRn inhibitor Vyvgart, a simpler administration route for the med will form a key piece of the Dutch immunology specialist’s expansion plans.
